Ascendis Pharma A/S
ASND | NASDAQ
$250.89
-$0.38 (-0.15%)
Nov 2, 2026, 11:48 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -50.13 | -20.36 | -13.33 | -10.97 | -16.90 | -16.48 |
PEG Ratio | 1.13 | 0.86 | 0.75 | -0.23 | 1.09 | -0.22 |
PS Ratio | 15.90 | 21.17 | 24.05 | 124.97 | 833.09 | 993.40 |
PB Ratio | -67.58 | -72.81 | -44.02 | 24.28 | 7.33 | 8.24 |
P/FCF Ratio | 252.17 | -25.02 | -13.65 | -12.54 | -14.66 | -23.57 |
P/OCF Ratio | 212.47 | -25.14 | -13.72 | -12.90 | -15.51 | -25.44 |
OCF/S Ratio | 7.48 | -84.20 | -175.23 | -968.65 | -5.37K | -3.91K |
Debt / Equity Ratio | -5.35 | -8.10 | -5.10 | 2.35 | 0.24 | 0.11 |
Quick Ratio | 0.76 | 0.84 | 0.67 | 1.11 | 7.28 | 14.02 |
Current Ratio | 1.04 | 1.17 | 0.95 | 1.29 | 8.03 | 14.02 |
Asset Turnover | 0.53 | 0.31 | 0.32 | 0.05 | 0.01 | 0.01 |
Interest Coverage | -1.69 | -4.26 | -10.34 | -18.31 | -115.52 | -172.38 |
Return on Equity | 134.58% | 357.68% | 330.44% | -221.45% | -43.41% | -49.95% |
Return on Assets | -16.82% | -32.05% | -58.32% | -53.52% | -35.36% | -42.76% |
Return on Invested Capital | -18.19% | -36.53% | -86.85% | -70.25% | -45.20% | -35.39% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 85.08% | 87.83% | 83.36% | 76.28% | 54.71% | 100% |
Net Profit Margin | -31.67% | -103.97% | -180.51% | -1.14K% | -4.93K% | -6.03K% |
Pretax Profit Margin | -29.53% | -102.64% | -177.77% | -1.13K% | -4.94K% | -6.03K% |
Operating Profit Margin | -18.92% | -76.66% | -170.79% | -1.1K% | -5.81K% | -4.76K% |
FCF Margin | 6.31% | -84.60% | -176.14% | -996.97% | -5.68K% | -4.22K% |
EBITDA Margin | -15.87% | -79.76% | -154.16% | -1.03K% | -4.69K% | -5.87K% |
Add to Watchlist
Select watchlists to add or remove ASND